ArticleFrontiers in pharmacology2025
Case Report: Osimertinib-induced acute interstitial lung disease.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Osimertinib-induced interstitial lung disease insights from faers signal detection and network toxicology analysis.BMC cancer · 2026Article
- Integrated Network Toxicology and Metabolomics Elucidate Mechanisms of Carbosulfan-Induced Respiratory Toxicity in Rats.International journal of molecular sciences · 2026Article
- Case Report: Furmonertinib-induced acute interstitial lung disease.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osimertinib is a third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively targets EGFR-TKI-sensitive mutations, thereby inhibiting tumor cell proliferation, migration, and invasion. Herein, we present a case of osimertinib-induced interstitial lung disease (ILD) in an 80-year-old woman with EGFR-mutated lung adenocarcinoma. The patient was treated with osimertinib as first-line therapy for metastatic non-small cell lung cancer (NSCLC). On day 45 of treatment, she experienced acute onset of severe dyspnea, which rapidly progressed to diffuse bilateral pulmonary consolidation and profound hypoxemia. Despite discontinuation of osimertinib and administration of aggressive supportive care, her clinical condition continued to deteriorate, ultimately resulting in a fatal outcome. This case underscores the importance of monitoring respiratory symptoms in patients receiving EGFR-TKIs, promptly diagnosing ILD, and implementing early intervention to mitigate adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.